Evaluating Amino Acid PETMRI to Improve Diagnosis and Treatment Planning of Glioma and Brain Metastases

What this Trial Is About

Researchers are investigating the use of amino acid PET combined with MRI to improve the diagnosis and assessment of brain tumors, specifically gliomas and brain metastases. The study aims to overcome limitations of MRI alone in identifying tumor grade, extent, and distinguishing viable tumor tissue from treatment effects or recurrences. Three promising amino acid PET tracers 11C-MET, 18F-FET, and 18F-FACBC are being evaluated to enhance diagnostic accuracy and treatment planning for these brain conditions. The study includes three substudies one involving 20 low-grade and 40 high-grade glioma patients examined with 18F-FACBC PETMRI at baseline and 4-6 months post-surgery, with some also receiving 18F-FET PETMRI for comparison another focusing on 30 recurrent high-grade glioma patients undergoing 11C-MET PETMRI at baseline and one month after Gamma Knife radiosurgery and a third enrolling patients with brain metastases who will receive amino acid PETMRI at baseline, one month after surgery or stereotactic radiosurgery, and when recurrence is suspected. Participants will undergo PETMRI scans at specified time points depending on their diagnosis and treatment plan. Researchers will assess diagnostic accuracy in detecting tumor tissue, differentiate recurrence from treatment-induced changes, and evaluate therapy response. The study monitors patients health status and imaging results over several months to improve brain tumor diagnosis and management. Total participation time varies by subgroup and treatment schedule.

Diagnostic Assessment of Amino Acid PET/MRI in the Evaluation of Glioma and Brain Metastases